Show simple item record

dc.contributor.authorExarchou, K.
dc.contributor.authorHu, H.
dc.contributor.authorStephens, N. A.
dc.contributor.authorMoore, A. R.
dc.contributor.authorKelly, M.
dc.contributor.authorLamarca, Angela
dc.contributor.authorMansoor, Was
dc.contributor.authorHubner, Richard A
dc.contributor.authorMcNamara, Mairead G
dc.contributor.authorSmart, H.
dc.contributor.authorHowes, N. R.
dc.contributor.authorValle, Juan W
dc.contributor.authorPritchard, D. M.
dc.date.accessioned2022-08-31T11:38:30Z
dc.date.available2022-08-31T11:38:30Z
dc.date.issued2022en
dc.identifier.citationExarchou K, Hu H, Stephens NA, Moore AR, Kelly M, Lamarca A, et al. Endoscopic surveillance alone is feasible and safe in type I gastric neuroendocrine neoplasms less than 10 mm in diameter. Endocrine. 2022 Jul 27. PubMed PMID: 35895180. Epub 2022/07/28. eng.en
dc.identifier.pmid35895180en
dc.identifier.doi10.1007/s12020-022-03143-3en
dc.identifier.urihttp://hdl.handle.net/10541/625540
dc.description.abstractPurpose: Type I gastric neuroendocrine neoplasms (g-NENs) have a low risk of metastasis and a generally favourable prognosis. Patients with small type I g-NENs (≤10 mm) frequently require no treatment, whereas those with larger polyps usually undergo resection. We evaluated the safety and outcomes of endoscopic surveillance after no initial treatment in selected patients with type I g-NENs. Methods: Retrospective analysis of type I g-NEN patients across two European Neuroendocrine Tumour Society Centers of Excellence 2003-2019. Results: Following initial assessment, 87 of 115 patients with type I g-NEN (75 with polyps ≤10 mm) received no initial treatment and underwent endoscopic surveillance. 79/87 (91%) demonstrated no clinically meaningful change in tumour size or grade over a median 62 month follow up. Only two patients developed NEN progression that required a change in management and two other patients developed gastric adenocarcinoma/high grade dysplasia; all four initially had ≥11 mm g-NENs. Conclusions: Patients with ≤10 mm type I g-NENs were unlikely to develop clinically significant tumour progression and in most cases, resection was not needed. The endoscopic surveillance interval could therefore potentially be safely increased to every 2-3 years in such patients. However, lifelong surveillance is still advocated due to the additional risk of developing gastric adenocarcinoma.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1007/s12020-022-03143-3en
dc.titleEndoscopic surveillance alone is feasible and safe in type I gastric neuroendocrine neoplasms less than 10 mm in diameteren
dc.typeArticleen
dc.contributor.departmentDepartment of Molecular and Clinical Cancer Medicine, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UKen
dc.identifier.journalEndocrineen
dc.description.noteen]
refterms.dateFOA2022-08-31T12:13:00Z


Files in this item

Thumbnail
Name:
35895180.pdf
Size:
760.9Kb
Format:
PDF
Description:
Identified with Open Access button

This item appears in the following Collection(s)

Show simple item record